The therascreen PITX2 Assay

“A CE-marked clinically validated biomarker assay”

The therascreen PITX2 RGQ PCR Kit has been developed by Therawis Diagnostics together with its development partner Qiagen using reliable RGQ PCR technology and routinely available FFPE tissue.

The therascreen PITX2 RGQ PCR Kit is CE-certified and commercially available since February 2018.



Clinical Services

“Clinical Services provided by Therawis Pharma”

Therawis Pharma has established a European-wide network with oncology specialists. We have a proven track record for improving patient enrolment through interaction with study sites and key opinion leaders (KOL) in the following countries: